10x Genomics Inc Class A
TXG
$0.47 (-4.28%)
1D
1W
3M
1Y
5Y
ALL
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 20 days ago • TXG
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a BetZacks Investment Research • 28 days ago • TXG
10x Genomics (TXG) Upgraded to Buy: Here's What You Should KnowPRNewsWire • about a month ago • TXG
10x Genomics Announces Patent Litigation Settlement Agreement with BrukerZacks Investment Research • about a month ago • TXG
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to TradeSeeking Alpha • about a month ago • TXG
10x Genomics, Inc. (TXG) Q1 2025 Earnings Call TranscriptCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.